Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-DEP + PD-1 antibody
- Development stage
- Unknown
- Lead developer
- Beijing Friendship Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
L-DEP + PD-1 antibody is a combination regimen used as an induction therapy, particularly studied for Epstein-Barr virus-positive lymphomas such as lymphohistiocytosis. The L-DEP regimen consists of PEG-asparaginase, liposomal doxorubicin, etoposide, and methylprednisolone. This multi-agent chemotherapy is combined with a programmed cell death protein 1 (PD-1) monoclonal antibody (such as pembrolizumab or nivolumab), which acts as an immune checkpoint inhibitor. The rationale behind this combination is to leverage the cytotoxic effects of chemotherapy alongside the immunomodulatory action of PD-1 blockade, aiming to enhance antitumor immune responses and improve clinical outcomes[1][3]. The specific PD-1 antibody used may vary depending on trial design.
- Other names
- L-DEP and PD-1 antibodyL-DEP/DEP Regimen and PD-1 AntibodyPD-1 antibody-Beijing Friendship Hospital-hemophagocytic lymphohistiocytosis (EBV-associated)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on L-DEP + PD-1 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-DEP + PD-1 antibody.